logo

Personalized Neurostimulation Approach for the Treatment of Depression

Sector: Hospital • Location: Denmark

Source: EU Funding & Tenders Portal

Project
Ended

Depression currently affects more than 300 million people worldwide, that is an increase of over 18% between 2005 and 2015. Moreover, 50% of major depressions are untreated in Europe, costing about €170Bn per year. Despite subject´s relevance, there are not any efficient nor customized treatment options, these falling often within conventional solutions (e.g. cognitive techniques), medication or n

Status
Closed
Sector
Hospital, Residential
Location
Denmark
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Personalized Neurostimulation Approach for the Treatment of Depression

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Personalized Neurostimulation Approach for the Treatment of Depression” is an infrastructure initiative in the Hospital sector, located in Denmark. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Depression currently affects more than 300 million people worldwide, that is an increase of over 18% between 2005 and 2015. Moreover, 50% of major depressions are untreated in Europe, costing about €170Bn per year. Despite subject´s relevance, there are not any efficient nor customized treatment options, these falling often within conventional solutions (e.g. cognitive techniques), medication or neurostimulation techniques that do not acknowledge an individual rehabilitation for the patient. Platoscience has developed the world’s first plug n’ play device based on trans-cranial direct current neurostimulation (tDCS) for a personalised at-home treatment of depression. The patent-protected device, PlatoCure, consists of a portable neurostimulation headset with two programmable electrodes, easy to use and control, connected to an app to be tracked by health professionals and for cloud data collection and predictive analytics to improve individual treatment. PlatoCure also includes online neuroimaging by electroencephalogram (EEG) that enables measuring of electrophysiological data during stimulation. This yields a significant advantage of PlatoCure against competition, strengthening market introduction to become the standard treatment device for moderate to severe depression, yielding benefits for a large group of stakeholders, including patients, medical professionals, hospitals and clinics. The SME Ph1 will be crucial for: i) establishing partnerships with relevant stakeholders on an international level in the medical segment, ii) setting up a regulatory strategy and iii) developing a clear commercialisation strategy. Hereafter, PlatoScience will be able to start SME Ph 2 focusing on the clinical validation of the device with hospitals and clinics. Until the end of 2026, we expect a cumulative revenue of €10,1 million, gross profit of €8,25 million and to create 15 qualified new jobs, within 5 years of commercialization.

Location

Country

Denmark

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Residential

Article published date

2026-02-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project